ArticleBiomedical reports2016
piR-651 and its function in 95-D lung cancer cells.
Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Emerging roles of PIWI-interacting RNAs in cancer molecular diagnostics and therapeutics: a molecular biosciences perspective.Frontiers in molecular biosciences · 2026Review
- Transcriptional Control of PI3K/AKT/mTOR by piRNA-651 in Breast Carcinoma.Iranian biomedical journal · 2025Article
- A robust machine learning model based on ribosomal-subunit-derived piRNAs for diagnostic potential of nonsmall cell lung cancer across multicentre, large-scale of sequencing data.Clinical and translational medicine · 2025Article
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2025Review
- Review
- Triple‑negative breast cancer cell‑derived piR‑31115 promotes the proliferation and migration of endothelial cells via METTL3‑mediated m6A modification of YAP1.Oncology reports · 2025Article
- Review
- Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The potential role of PIWI-interacting RNAs in non-small cell lung cancer.Frontiers in oncology · 2025Review
- Critical appraisal of the piRNA-PIWI axis in cancer and cancer stem cells.Biomarker research · 2024Review
- Changes in the small noncoding RNA transcriptome in osteosarcoma cells.Journal of orthopaedic surgery and research · 2023Article
- Non-Coding RNAs in Human Cancer and Other Diseases: Overview of the Diagnostic Potential.International journal of molecular sciences · 2023Review
- PiRNA Obtained through Liquid Biopsy as a Possible Cancer Biomarker.Diagnostics (Basel, Switzerland) · 2023Review
- The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers.Molecular cancer · 2023Review
- PIWIL1 interacting RNA piR-017724 inhibits proliferation, invasion, and migration, and inhibits the development of HCC by silencing PLIN3.Frontiers in oncology · 2023Article
- Pan-cancer landscape of immunology PIWI-interacting RNAs.Computational and structural biotechnology journal · 2023Article
- Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2022Article
- PIWI-interacting RNA (piRNA): a narrative review of its biogenesis, function, and emerging role in lung cancer.Asian biomedicine : research, reviews and news · 2022Review
- PIWI-interacting RNAs in cancer: Biogenesis, function, and clinical significance.Frontiers in oncology · 2022Review
- PIWI interacting RNAs perspectives: a new avenues in future cancer investigations.Bioengineered · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PIWI-associated RNAs (piRNAs or piRs), a new-found class of small non-coding RNAs, which are mainly expressed in germline cells and partly in somatic lines, have a vital role in carcinogenesis by maintaining genomic integrity and regulation of epigenetics. The previous studies have confirmed that the expression of piR-651 is upregulated in several cancer tissue and cell lines, including lung cancer. However, the mechanism of carcinogenesis and piR-651 remains to be elucidated. Therefore, the present study assessed the 95-D high metastasis human lung cancer cell line to detect the effect of piR-651 on carcinogenesis. Firstly, piR-651 promoted the high metastasis characteristic of the 95-D cell lines by Transwell and wound-healing assays. The influence of piR-651 on tumor cell proliferation and apoptosis was detected by the MTT assay and flow cytometry. In conclusion, piR-651 may be an oncogene in lung cancer formation and development. Therefore, piR-651 regulated carcinogenesis by influencing cell proliferation, apoptosis, migration and invasion, and may be a potential tumor marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.